eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
NOWOŚĆ
Portal dla gastroenterologów!
www.egastroenterologia.pl
SCImago Journal & Country Rank
3/2017
vol. 12
 
Poleć ten artykuł:
Udostępnij:
więcej
 
 
streszczenie artykułu:
Artykuł oryginalny

Blood serum levels of E-cadherin in patients with colorectal cancer

Dariusz Cepowicz, Konrad Zaręba, Anna Pryczynicz, Tomasz Dawidziuk, Joanna Żurawska, Joanna Hołody-Zaręba, Mariusz Gryko, Bogusław Kędra

Data publikacji online: 2017/09/30
Pełna treść artykułu
Pobierz cytowanie
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 


Introduction: Colorectal cancer is the second most common cancer in terms of incidence in Poland. It is also the second most common cause of cancer deaths in men and the third women. In 75–80% of cases, depending on sources, it is of an occasional nature, and in the remaining 20–25% it has a hereditary character.

Aim: To compare the levels of E-cadherin in blood serum with some histopathological and clinical features. E-cadherin is an adhesion molecule, loss of function of which is suspected to influence both cancer progression and metastasis.

Material and methods: The study group comprised 48 patients diagnosed with colorectal cancer treated surgically in the Second Department of General and Gastroenterological Surgery, Medical University Hospital in Bialystok.

Results: As has been shown here, there is no statistically significant relationship between the levels of E-cadherin in blood serum and the possible prognosis to the progression of colorectal cancer. However, it was indicated that there appears to be a statistically significant relationship between blood serum E-cadherin levels and the levels of alanine aminotransferase and aspartate aminotransferase in patients with colorectal cancer.

Conclusions: The authors suggest that this significance may require further study.
referencje:
Didkowska J, Wojciechowska U, Zatoński W. Cancer in Poland in 2009. Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie, Warsaw 2011.
Łacko A. Colorectal cancer. Post Nauk Med 2011; 24: 137-45.
Ahmed RL, Schmitz KH, Anderson KE, et al. The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006; 107: 28-36.
Mantur M, Wojszel J. Cząsteczki adhezyjne oraz ich udział w procesie zapalnym i nowotworowym. Pol Merk Lek 2008; 24: 177-80.
Tsanou E, Peschos D, Batistatou A, et al. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res 2008; 28 (6A): 3815-26.
Kwiatkowski P, Godlewski J, Śliwińska-Jewsiewicka A, et al. Cell adhesion molecules in the process of carcinogenesis and metastasis. Pol Ann Med 2009; 16: 128-37.
Paschos KA, Canovas D, Bird NC. The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal 2009; 21: 665-74.
Kouso H, Yano T, Maruyama R, et al. Differences in the expression of epithelial-mesenchymal transition related molecules between primary tumors and pulmonary metastatic tumors in colorectal cancer. Surg Today 2013; 43: 73-80.
Soyama A, Eguchi S, Takatsuki M, et al. Significance of the serum level of soluble E-cadherin in patients with HCC. Hepatogastroenterology 2008; 55: 1390-3.
Inge LJ, Barwe SP, D’Ambrosio J, et al. Soluble E-cadherin promotes cell survival by activating epidermal growth factor receptor. Exp Cell Res 2011; 317: 838-48.
Lu MH, Huang CC, Pan MR, et al. Prospero homeobox 1 promotes epithelial-mesenchymal transition in colon cancer cells by inhibiting E-cadherin via miR-9. Clin Cancer Res 2012; 18: 6416-25.
Dorudi S, Hanby AM, Poulsom R, et al. Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer 1995; 71: 614-6.
Hardy RG, Tselepis C, Hoyland J, et al. Aberrant P-cadherin expression is an early event in hyperplastic and dysplastic transformation in the colon. Gut 2002; 50: 513-9.
Weiss JV, Klein-Scory S, Kübler S, et al. Soluble E-cadherin as a serum biomarker candidate: elevated levels in patients with late-stage colorectal carcinoma and FAP. Int J Cancer 2011; 128: 1384-92.
Okugawa Y, Toiyama Y, Inoue Y, et al. Clinical significance of serum soluble E-cadherin in colorectal carcinoma. J Surg Res 2012; 175: e67-73.
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe